Home
Product
Antibody
Biosimilar Antibodies
C2 (Empasiprubart Biosimilar) Recombinant Monoclonal Antibody

C2 (Empasiprubart Biosimilar) Recombinant Monoclonal Antibody

Code: CSB-RA003658MB1HU

Rate （N/A）
Review （0）

Size:

100ug

100ug500ug1mg5mg10mg50mg100mg200mg

US$199

Quantity:

Species Reactivity: Human

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

P06681

Alternative Names

ARGX 117 research-grade biosimilar; ARGX-117 research-grade biosimilar; empasiprubart research-grade biosimilar ;C2 antibody; Complement C2 antibody; C3/C5 convertase [Cleaved into: Complement C2a antibody; Serine protease complement C2b antibody; EC 3.4.21.43] antibody

Species Reactivity

Human

Immunogen

Recombinant Human C2 protein

Conjugate

Non-conjugated

Clonality

Monoclonal

Buffer

0.01M PBS，pH7.4

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Notes

Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.

Lead Time

3-4 weeks
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Concentration

It differs from different batches. Please contact us to confirm it.

Usage

It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Datasheet & COA

Antibody FAQs

Description

This recombinant monoclonal antibody is a research-grade biosimilar of empasiprubart (ARGX-117), targeting complement component C2, a soluble complement protein that is essential to the classical and lectin pathways. Upon pathway activation, C2 associates with C4b to form the C4bC2 (C3 proconvertase) complex, which is then processed to generate the C3 convertase (C4b2a)—a central enzymatic step that amplifies complement activation and drives downstream effector processes such as opsonization, inflammatory mediator release, and terminal pathway activation.

Empasiprubart is described as a humanized “sweeping” anti-C2 monoclonal antibody with pH- and Ca²⁺-dependent binding, designed to inhibit C2 function and thereby block classical/lectin pathway activation upstream of C3 by preventing formation of the C4bC2 complex. This biosimilar enables researchers to investigate C2-driven complement biology, including pathway initiation/amplification mechanisms and complement-dependent injury models, and to develop/benchmark assays that quantify classical/lectin pathway inhibition (e.g., C3 deposition readouts) in controlled experimental systems.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

Component C2 which is part of the classical pathway of the complement system is cleaved by activated factor C1 into two fragments: C2b and C2a. C2a, a serine protease, then combines with complement factor C4b to generate the C3 or C5 convertase.

Gene References into Functions

Vag8 binding to human C1-inhibitor (C1-inh) interferes with the binding of C1-inh to C1s, C1r and MASP-2, resulting in the release of active proteases that subsequently cleave C2 and C4 away from the bacterial surface. PMID:28742139
Solution Structures of Complement C2 and Its C4 Complexes Propose Pathway-specific Mechanisms for Control and Activation of the Complement Proconvertases. PMID:27252379
The rs2844455 A allele of C2 is a risk factor for systemic lupus erythematosus development in a Chinese population, whereas the G allele might be a protective factor. PMID:26176736
our data indicate that C2 rs547154 polymorphism plays a protective role in the development of PCV. PMID:25732348
Inhibition of c3 convertase activity by hepatitis C virus as an additional lesion in the regulation of complement components. PMID:24983375
These overall results suggest a lack of strong association with the C2 and C7 gene polymorphisms to the susceptibility of systemic lupus erythematosus in the Malaysian population. PMID:21881993
Results showed that missense mutations in transmembrane protein 2 p.Ser1254Asn, interferon alpha 2 p.Ala120Thr, its regulator NLR family member X1 p.Arg707Cys, and complement component 2 p.Glu318Asp were associated with chronic hepatitis B. PMID:22610944
CFH (RS1061170), C2 (RS547154), OR CFB (RS438999) was not associated with early or late AMD. PMID:23060141
These data suggest that patients with C2 deficiency are at increased risk of Streptococcus pyogenes infections. PMID:20417301
C2 microheterogeneity and histocompatibility antigens Class I were studied in an Austrian population. PMID:12823772
study of the formation of high affinity C5 convertase of the classical pathway of complement PMID:12878586
Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2 PMID:16670774
a weaker, independent protective effect exists for complement component 2 in age related macular degeneration. PMID:17576744
These data confirm that the classical pathway is vital for complement-mediated phagocytosis of S. pneumoniae and demonstrate why subjects with a C2 deficiency have a marked increase in susceptibility to S. pneumoniae infections. PMID:18541650
Study provides insights into the genetic pathogenesis of AMD, and C2 has been shown as one of the five genes independently involved in progression from intermediate disease to advanced disease in which blindness is frequent. PMID:19015224
Upon cleavage by C1s, C2a domains undergo conformational rotation while bound to C4b and the released C2b domains may remain folded together as seen in the intact protein. PMID:19237749